Cargando…

Folate-Targeted Nanoliposomal Chemophototherapy

Light-responsive liposomes have been developed for the on-demand release of drugs. However, efficient delivery of chemotherapeutic drugs to tumor for cancer theranostics remains a challenge. Herein, folic acid (FA), an established ligand for targeted drug delivery, was used to decorate light-sensiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Chitgupi, Upendra, Qin, Yiru, Ghosh, Sanjana, Quinn, Breandan, Carter, Kevin, He, Xuedan, Sunar, Ulas, Lovell, Jonathan F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609802/
https://www.ncbi.nlm.nih.gov/pubmed/37896144
http://dx.doi.org/10.3390/pharmaceutics15102385
_version_ 1785128100434018304
author Chitgupi, Upendra
Qin, Yiru
Ghosh, Sanjana
Quinn, Breandan
Carter, Kevin
He, Xuedan
Sunar, Ulas
Lovell, Jonathan F.
author_facet Chitgupi, Upendra
Qin, Yiru
Ghosh, Sanjana
Quinn, Breandan
Carter, Kevin
He, Xuedan
Sunar, Ulas
Lovell, Jonathan F.
author_sort Chitgupi, Upendra
collection PubMed
description Light-responsive liposomes have been developed for the on-demand release of drugs. However, efficient delivery of chemotherapeutic drugs to tumor for cancer theranostics remains a challenge. Herein, folic acid (FA), an established ligand for targeted drug delivery, was used to decorate light-sensitive porphyrin-phospholipid (PoP) liposomes, which were assessed for FA-targeted chemophototherapy (CPT). PoP liposomes and FA-conjugated PoP liposomes were loaded with Doxorubicin (Dox), and physical properties were characterized. In vitro, FA-PoP liposomes that were incubated with FA receptor-overexpressing human KB cancer cells showed increased uptake compared to non-targeted PoP liposomes. Dox and PoP contributed towards chemophototherapy (CPT) in vitro, and PoP and FA-PoP liposomes induced cell killing. In vivo, mice bearing subcutaneous KB tumors treated with PoP or FA-PoP liposomes loaded with Dox, followed by 665 nm laser treatment, had delayed tumor growth and improved survival. Dox delivery to tumors increased following laser irradiation for both PoP and FA-PoP liposomes. Thus, while Dox-FA-PoP liposomes were effective following systemic administration and local light irradiation in this tumor model, the FA targeting moiety did not appear essential for anti-tumor responses.
format Online
Article
Text
id pubmed-10609802
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106098022023-10-28 Folate-Targeted Nanoliposomal Chemophototherapy Chitgupi, Upendra Qin, Yiru Ghosh, Sanjana Quinn, Breandan Carter, Kevin He, Xuedan Sunar, Ulas Lovell, Jonathan F. Pharmaceutics Article Light-responsive liposomes have been developed for the on-demand release of drugs. However, efficient delivery of chemotherapeutic drugs to tumor for cancer theranostics remains a challenge. Herein, folic acid (FA), an established ligand for targeted drug delivery, was used to decorate light-sensitive porphyrin-phospholipid (PoP) liposomes, which were assessed for FA-targeted chemophototherapy (CPT). PoP liposomes and FA-conjugated PoP liposomes were loaded with Doxorubicin (Dox), and physical properties were characterized. In vitro, FA-PoP liposomes that were incubated with FA receptor-overexpressing human KB cancer cells showed increased uptake compared to non-targeted PoP liposomes. Dox and PoP contributed towards chemophototherapy (CPT) in vitro, and PoP and FA-PoP liposomes induced cell killing. In vivo, mice bearing subcutaneous KB tumors treated with PoP or FA-PoP liposomes loaded with Dox, followed by 665 nm laser treatment, had delayed tumor growth and improved survival. Dox delivery to tumors increased following laser irradiation for both PoP and FA-PoP liposomes. Thus, while Dox-FA-PoP liposomes were effective following systemic administration and local light irradiation in this tumor model, the FA targeting moiety did not appear essential for anti-tumor responses. MDPI 2023-09-26 /pmc/articles/PMC10609802/ /pubmed/37896144 http://dx.doi.org/10.3390/pharmaceutics15102385 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chitgupi, Upendra
Qin, Yiru
Ghosh, Sanjana
Quinn, Breandan
Carter, Kevin
He, Xuedan
Sunar, Ulas
Lovell, Jonathan F.
Folate-Targeted Nanoliposomal Chemophototherapy
title Folate-Targeted Nanoliposomal Chemophototherapy
title_full Folate-Targeted Nanoliposomal Chemophototherapy
title_fullStr Folate-Targeted Nanoliposomal Chemophototherapy
title_full_unstemmed Folate-Targeted Nanoliposomal Chemophototherapy
title_short Folate-Targeted Nanoliposomal Chemophototherapy
title_sort folate-targeted nanoliposomal chemophototherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609802/
https://www.ncbi.nlm.nih.gov/pubmed/37896144
http://dx.doi.org/10.3390/pharmaceutics15102385
work_keys_str_mv AT chitgupiupendra folatetargetednanoliposomalchemophototherapy
AT qinyiru folatetargetednanoliposomalchemophototherapy
AT ghoshsanjana folatetargetednanoliposomalchemophototherapy
AT quinnbreandan folatetargetednanoliposomalchemophototherapy
AT carterkevin folatetargetednanoliposomalchemophototherapy
AT hexuedan folatetargetednanoliposomalchemophototherapy
AT sunarulas folatetargetednanoliposomalchemophototherapy
AT lovelljonathanf folatetargetednanoliposomalchemophototherapy